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Abstract
Background: The study aimed to investigate the pharmacokinetics of intravenous ciprofloxacin and the adequacy
of 400 mg every 12 hours in critically ill Intensive Care Unit (ICU) patients on continuous veno-venous
haemodiafiltration (CVVHDF) with particular reference to the effect of achieved flow rates on drug clearance.
Methods: This was an open prospective study conducted in the intensive care unit and research unit of a
university teaching hospital. The study population was seven critically ill patients with sepsis requiring CVVHDF.
Blood and ultrafiltrate samples were collected and assayed for ciprofloxacin by High Performance Liquid Chromatography
(HPLC) to calculate the model independent pharmacokinetic parameters; total body clearance (TBC), half-life (t1/2)a n d
volume of distribution (Vd). CVVHDF was performed at prescribed dialysate rates of 1 or 2 L/hr and ultrafiltration rate of 2 L/
hr. The blood flow rate was 200 ml/min, achieved usingaG a m b r ob l o o dp u m pa n dH o spal AN69HF haemofilter.
Results: Seventeen profiles were obtained. CVVHDF resulted in a median ciprofloxacin t1/2 of 13.8 (range 5.15-39.4)
hr, median TBC of 9.90 (range 3.10-13.2) L/hr, a median Vdss of 125 (range 79.5-554) L, a CVVHDF clearance of 2.47
+/-0.29 L/hr and a clearance of creatinine (Clcr) of 2.66+/-0.25 L/hr. Thus CVVHDF, at an average flow rate of ~3.5 L/
hr, was responsible for removing 26% of ciprofloxacin cleared. At the dose rate of 400 mg every 12 hr, the median
estimated Cpmax/MIC and AUC0-24/MIC ratios were 10.3 and 161 respectively (for a MIC of 0.5 mg/L) and exceed
the proposed criteria of >10 for Cpmax/MIC and > 100 for AUC0-24/MIC. There was a suggestion towards increased
ciprofloxacin clearance by CVVHDF with increasing effluent flow rate.
Conclusions: Given the growing microbial resistance to ciprofloxacin our results suggest that a dose rate of 400
mg every 12 hr, may be necessary to achieve the desired pharmacokinetic - pharmacodynamic (PK-PD) goals in
patients on CVVHDF, however an extended interval may be required if there is concomitant hepatic impairment. A
correlation between ciprofloxacin clearance due to CVVHDF and creatinine clearance by the filter was observed (r
2
= 0.76), providing a useful clinical surrogate marker for ciprofloxacin clearance within the range studied.
Trial Registration: Current Controlled Trials ISRCTN52722850
Background
Severe sepsis is a significant contributor to Intensive
Care Unit (ICU) admission and reports vary from 12%
to 27% of ICU admissions in different countries [1].
Many more patients develop sepsis following ICU
admission. EPIC 2 demonstrated that 51% of ICU
inpatients were classified as infected on the day of the
point prevalence study. In this study 62% of isolates
were identified to be Gram negative, which is worrisome
given the dearth of in-development antimicrobials with
gram negative coverage [2]. Under dosing of antibiotics
has enabled the genesis of resistant strains and this is
particularly an issue with fluoroquinolones, aminoglyco-
sides and beta lactams [3,4]. Of particular concern is the
ability of fluoroquinolones to engender resistance to
other classes of antibiotics [5]. Altered drug
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antimicrobial drug clearance in critically ill patients
(antibiotic regimens are often developed on the basis of
drug disposition in non-critically ill volunteers) and
further complicates the selection of appropriate dosing
schedules for these patients. For optimal dosing, it is
necessary to consider the kill characteristics of the
antibiotic.
Pharmacokinetic-pharmacodynamic (PK-PD) para-
meters can be used to indicate the potential for bacterial
eradication with antimicrobial therapy. Bactericidal
activity can be time-dependent or concentration-depen-
dent. Quinolones exhibit concentration-dependent bac-
terial killing [6-10]. Consequently bactericidal activity
becomes more pronounced as serum drug concentra-
tions increase to approximately 10 times the minimum
inhibitory concentration (MIC.). The goal of ciprofloxa-
cin therapy is to maximise the 24-hr AUC/MIC and the
peak/MIC ratios [10]. There is general concern about
the emergence of resistance as a result of inadequate
doses of ciprofloxacin [9]. A Cpmax/MIC ratio, where
Cpmax is the maximum steady state serum concentration,
of >10 and an AUC24/MIC ~> 100 have been proposed
as predictors of therapeutic efficacy [10-12]. In clinical
practice, Cpmax is equated with the serum peak level. A
number of papers have highlighted the requirement for
a re-evaluation of currently recommended antimicrobial
dosage regimens for critically ill patients [13,14].
Ciprofloxacin disposition is affected by critical illness,
particularly by the presence of organ failure and dosage
adjustment is advised in patients with renal failure [15].
In patients with severely impaired renal function, a 50%
dosage reduction has been recommended [16]. Some
data are extrapolated from non-critical patients with
renal failure and others from critically ill patients with-
out renal failure. Doses ranging from 200 mg twice daily
to 400 mg three times daily have been used for critically
ill patients without renal impairment [17,18].
Renal elimination, including both glomerular filtration
and tubular secretion accounts for approximately 66% of
ciprofloxacin clearance [19]. In healthy volunteers, the
hepatic route accounts for approximately 20% of elimi-
nation, with transintestinal excretion also playing a pos-
sibly significant role. This is thought to represent a
notable compensatory pathway preventing drug accumu-
lation in renal failure. In terms of clearance during con-
tinuous renal replacement therapy (CRRT), the method
of CRRT used has been presented as an important
determinant of the effect of CRRT on clearance, with
increased drug clearance via CVVHDF compared to
continuous veno-venous haemofiltration (CVVH) [20].
Nonetheless, clearance via CVVH of up to 25% has been
reported [21]. It has been recommended therefore that
dosing during CVVHDF is focussed on attaining
clinically adequate drug concentrations, preferably with
concurrent therapeutic drug monitoring.
As a result of the reported variability in ciprofloxacin
pharmacokinetic parameters during critical illness, dif-
ferences in patient populations and CRRT conditions in
literature reports and the absence of a consensus on
dosing regimens, a prospective pharmacokinetic evalua-
tion of ciprofloxacin during CVVHDF therapy was
undertaken.
Methods-
Patient Demographics and Clinical Characteristics
This was an open, prospective pharmacokinetic study in
a multidisciplinary, intensive care unit in a university
teaching hospital. Ethics approval was obtained from the
Joint Ethics Committee (St James’s/AMNCH) (Reference
Number 041008/7804). Clinical trial approval was
granted by the Irish Medicines Boards (EudraCT Num-
ber 2004-002195-42) and the trial was registered with
Current Clinical Trials (ISRCTN52722850). Consent
(predominantly consent by proxy) was obtained in com-
pliance with Helsinki declaration. Seven critically ill
patients, treated concurrently with intravenous cipro-
floxacin and CVVHDF therapy, were enrolled in the
study. Intravenous ciprofloxacin 400 mg twice daily
administered as a one hour infusion was the dosage
regimen generally employed, dosing at all times was at
the discretion of the physician. A dosage regimen of
ciprofloxacin 400 mg once daily was also analysed for
three patients, while a dosage regimen of 200 mg twice
daily was also assessed in one patient. MIC susceptibility
testing for pathogens isolated was not performed.
Instead a representative MIC of 0.5 mg/L was employed
based on an analysis of local ecology data. It should be
noted that CVVHDF patients in this hospital are pre-
scribed on average 14.3 drugs during CVVHDF, 4.7
+/-2.66 are anti-infectives.
CVVHDF conditions
CVVHDF was performed at prescribed dialysate rates of
1 or 2 L/hr and ultrafiltration rate of 2 L/hr. This
reflects the typical CVVHDF prescription of the unit.
The blood flow rate was 200 ml/min, achieved using a
Gambro blood pump and Hospal AN69HF haemofilter.
For patients 6 and 7, CVVHDF was run heparin-free,
due to coagulopathy.
Measurement of Ciprofloxacin Concentrations
Timed serum samples were collected during each
dosage interval and ultrafiltrate during 7 dosage inter-
vals (1 per patient). Effluent fluid was collected for the
entire dosage interval. The volume of each hourly batch
was recorded and a 40 ml sample was taken for analysis.
Aliquots from each sample were analysed for
Spooner et al. BMC Clinical Pharmacology 2011, 11:11
http://www.biomedcentral.com/1472-6904/11/11
Page 2 of 9ciprofloxacin concentration and for creatinine determi-
nation. Total ciprofloxacin concentrations in serum and
effluent were measured by the HPLC method of Davis
et al [22], adapted for both serum and effluent fluid ana-
lysis. Quantitation was based on external standard cali-
bration using the ratio of the peak areas of the analyte
and the internal standard (b-hydroxypropyl theophyl-
line). Replicate analysis was performed both on control
samples and study samples. Ciprofloxacin hydrochloride
monohydrate (1g) (gift from Bayer UK) was used to ver-
ify the concentration of the commercial infusion solu-
tion, Ciproxin
®. The extraction efficiency was in excess
of 80% in the concentration range 0.5-20.0 μg/ml and
the between day coefficient of variation <10%. Precision
was less than 5.0 R.S.D.%. The sensitivity of the assay
was 0.5 μg/ml.
Analysis of Serum Concentrations of Ciprofloxacin
Serum concentrations, from an indwelling arterial can-
nula, were measured immediately before the infusion
was started, immediately after the infusion finished and
at 2,3,4,6,8 and 12 hours post infusion where the dosage
interval was 12 hr. When the prescribed dosage interval
was 24 hr samples were also taken at 18 and 24 hrs.
Exact sampling times were recorded. Thus Cpmax was
directly measured.
Pharmacokinetic analysis
Calculating half-life and clearance
Non-compartmental pharmacokinetic methods were
used. Pharmacokinetic analysis was performed using
WinNonlin pharmacokinetic software, version 5.2,
(Pharsight Corporation, North Carolina, U.S.A.). The
terminal half-life (t1/2) was calculated as 0.693/lz,w h e r e
lz is the first order terminal elimination rate constant.
T h ea r e au n d e rt h ep l a s m ac o n c e n t r a t i o n - t i m ec u r v e s
(AUC) were calculated using the linear trapezoidal
method. AUC for the study period (n = 12 or 24 hours)
was used to calculate the AUC extrapolated to infinity
(AUC0-∞) by the equation AUC0-t* +C * / lz.w h e r eC *i s
the final plasma concentration, at the final sampling
time, t*. The Total Body Clearance (TBC) was calculated
as dose/AUC0-∞ for profile 4a as this was a first dose,
and as dose/AUC0-τ at steady state, where τ is the
dosage interval, for all other profiles except 2c, 4b and
6c, which were not at steady state.
Estimating clearance for profiles not at steady state
Profiles 2c, 4b and 6c did not result from initial doses,
a n dc o u l dn o tb ec o n s i d e r e dt ob ea ts t e a d ys t a t ea s
they directly followed a change in dose or interval. For
these profiles, TBC was estimated as dose/AUCn0-∞.
AUC n0-∞ in these cases was estimated as (AUC0-∞
-(C*(n-1)/lz( n - 1 ) )), where C*(n-1) was the final observed
concentration at the end of the preceding dose interval,
and lz( n - 1 )was the first order terminal elimination rate
constant calculated from the preceding dose interval.
Calculating volume of distribution at steady state (Vdss)
Because of the severity of illness body weights could
not be accurately monitored, consequently parameters
were not weight normalised. Volume of distribution
at steady state (Vdss) for an initial dose was calculated
as TBC × ((AUMC0−∞/AUC0−∞) − tinf/2),w h e r et inf
is the duration of the infusion, and as
TBC × (((AUMC0−τ + τ(AUC0−∞ − AUC0−τ))/AUC0−τ) − tinf/2)
from profiles at steady state. In cases where the dosing
interval was changed from 24 (at steady state) to 12
hours, the first profile following the change was calcu-
lated as a 24 hour interval, with sampling ceasing at 12
hours. This was the case for profiles 6b and 7b. Vdss
was not calculated for profiles 2c, 4b and 6c as these
were neither an initial dose or at steady state.
Calculating sieving coefficients
Sieving coefficients (S) for ciprofloxacin and creatinine
were calculated from the time-matched concentrations
in effluent and in serum for a single dosage interval,
whereby Screatinine =C effluent/Cserum and Scipro =C effluent/
Cserum. The clearance of creatinine was calculated from
Screatinine and the measured flow of effluent (Q) where
Clcreat =S creat xQ .
The fraction cleared by CVVHDF (FCVVHDF)w a s
determined from ClCVVHDF/TBC. The PK-PD para-
meters Cpmax/MIC and AUC0-24 /MIC were employed
as predictors of the likelihood of clinical and microbio-
logical response.
Results
Patients
Relevant demographic and clinical data relating to the
seven patients studied are presented in Table 1. Patients
were severely ill having renal failure, haemodynamic
instability and coagulopathy. Six patients were pre-
scribed ciprofloxacin for documented infection (Pseudo-
monas aeruginosa, Escherichia coli), while one patient
with suspected sepsis was prescribed ciprofloxacin
empirically. The median APACHE Π score was 27
(range 25-30).
CVVHDF conditions
The actual flow rates achieved were recorded and compared
with the target flow rates. The mean effluent flow rate
achieved was 3.35 +/- 0.50 L/hr (Range: 2.9 - 4.0 L/hr). The
mean duration of CVVHDF therapy was 9.3 +/- 3.7 days.
The mean number of filters used per dosage interval was
1.1. The mean duration of use of a filter was 50.6 hours.
Pharmacokinetic profiles
Seventeen pharmacokinetic profiles were obtained from
these seven patients. The ciprofloxacin pharmacokinetic
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netic profile, during treatment with CVVHDF are pre-
sented in Table 2. Ciprofloxacin t1/2 during CVVHDF
was variable, ranging from 5.15 to 39.4 hours, with a
median of 13.8 hours, reflecting a median elimination
rate constant of 0.050 (range 0.018-0.135) hr
-1.T h e
average t1/2 of patients 1 and 4 (both had hepatic
impairment) were 37.3 and 25.9 hours, respectively.
These t1/2 values are seven to eight times that obtained
in patients with normal renal function, and were the
highest obtained in the current study. Patient 4 had evi-
dence of liver injury that may have resulted in impaired
Table 1 Demographic and clinical data of patients on continuous veno-venous haemodiafiltration administered
ciprofloxacin
Sex Age Diagnosis Infective
pathogen
APACHE II score
(initial/highest)
CVVHDF
Duration(days)
ICU Mortality
Outcome
1 M 60 Intestinal Obstruction, Hemicolectomy Escherichia coli 26 6 Survived
2 F 77 Neutropaenic sepsis Pseudomonas aeruginosa 27 5 Died
3 F 68 Intestinal obstruction, post-operative sepsis
and acute renal failure
Pseudomonas aeruginosa 28 14 Survived
4 M 47 Acute pancreatitis, sepsis Escherichia Coli 25 14 Survived
5 F 71 ESRD with severe sepsis Empiric cover 27 8 Died
6 M 57 Hepatic cirrhosis with severe sepsis Pseudomonas Aeruginosa,
Enterococcus faecalis
29 7 Survived
7 M 28 Acute liver failure with severe sepsis Pseudomonas aeruginosa 30 11 Survived
Table 2 Estimates of pharmacokinetic parameters obtained from multiple ciprofloxacin serum concentrations in a
dosage interval using non-compartmental methods
Patient
Profile
Dose
(mg)
Dosage
Interval
(hours)
T1/2 (hrs) k
(hr
-1)
AUC0-τ*
(τ = dosage
interval)
(mg.hr/L)
TBC (Dose/AUC)
(L/hr)
Vdss
(L)
1.A 400 12 35.2 0.020 35.4 11.3 524
1.B 400 12 39.4 0.018 38.3 10.4 555
Mean 37.3 0.019 36.8 10.9 539
2.A 200 12 5.15 0.135 15.2 13.2 104
2.B 200 12 13.8 0.050 16.5 12.2 215
2.C 400 12 12.4 0.056 51.8 7.72
Mean 10.5 0.080 11.0 160
3.A 400 12 5.97 0.116 38.9 10.3 79.5
3.B 400 12 7.50 0.092 40.2 10.0 97.3
Mean 6.73 0.104 39.5 10.1 88.4
4.A 400 24 24.7 0.028 129 3.10 111
4.B 400 12 27.2 0.026 81.5 4.91
Mean 25.9 0.027 4.00
5.A 400 12 8.44 0.082 40.4 9.90 107
5.B 400 12 5.77 0.120 37.8 10.6 81.1
5.C 400 12 6.80 0.102 40.9 9.78 88.2
Mean 7.00 0.101 39.7 10.1 92.2
6.A 400 24 14.0 0.050 43.4 9.22 175
6.B 400 12 14.7 0.047 54.0 7.40 151
6.C 400 12 16.5 0.042 49.6 8.06
Mean 15.0 0.046 8.23 163
7.A 400 24 15.1 0.046 50.6 7.91 164
7.B 400 12 10.4 0.067 39.4 10.1 139
Mean 12.7 0.056 9.00 151
* τ taken to be 24 hours for first profile immediately following a change in prescribed dosage interval (profiles 6b and 7b)
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l i v e rd i s e a s e ,w h i c hm a yh a v ec o n t r i b u t e dt ot h ep r o -
longed t1/2. In patient 4, profile 4a, the clearance was
calculated using the estimated AUC0-∞,a st h i sp r o f i l e
was measured following the initial dose. The long half
life calculated (25 h) in combination with the lower
volume of distribution lead to a comparatively low esti-
mated TBC. The t1/2 observed in patients 3 and 5, 6.73
and 7.00 respectively, were closer to those seen in
patients with normal renal function. The median TBC
of ciprofloxacin was 9.90 (range 3.10-13.2) L/hr (~0.14
L/hr/kg based on a 70 kg patient). This value represents
hepatic, residual renal and transintestinal ciprofloxacin
clearance, in addition to ciprofloxacin clearance by the
filter. The Vdss for ciprofloxacin during CVVHDF ther-
apy ranged from 79.5-555 L with a median of Vdss of
125 L. The mean Cpmax concentration following admin-
istration of 400 mg every 12 hours was 5.8 +/- 1.0 mg/L.
The clearances of ciprofloxacin and creatinine by
CVVHDF are presented in Table 3. The mean clearance
of ciprofloxacin by CVVHDF was 2.47 +/- 0.29 L/hr,
thus the clearance of ciprofloxacin by CVVHDF was on
average 26% of the TBC, reflected in the mean FCVVHDF
of 0.26 (Table 3). This value excludes that of patient 4.
In this case a significant fraction (0.74) of the clearance
is calculated to have occurred via CVVHDF, and was
therefore considered an atypical value.
The Scipro was 0.70 +/- 0.06. A simple method for esti-
mating drug clearance through the filter, without mea-
suring drug levels, involves using the non-protein bound
fraction (fu) of ciprofloxacin as an estimate of the siev-
ing coefficient, as it is the unbound fraction that crosses
the filter. Hoffken et al [23] and Joos et al [24] have
reported fu values for ciprofloxacin of 0.6 and 0.78
respectively. Applying these values to the observed flow
rates in this study gives clearance estimates of 2.0 L/hr
and 2.7 L/hr, which approximate the measured value of
2.47 L/hr. The sieving coefficient for creatinine (0.82 +/-
0.04) was quite similar to that estimated for ciprofloxa-
cin. A correlation between ciprofloxacin clearance due
to CVVHDF (y) and creatinine clearance by the filter (x)
was observed (y = -0.29 + 1.03x, r
2 = 0.76) and is illu-
strated in Figure 1. Ciprofloxacin and creatinine clear-
ances over time were examined in order to identify any
change in filter efficiency over time. There was little var-
iation in filter performance as the clearance of both
creatinine and ciprofloxacin remaining relatively
constant.
Within the observed range of effluent flow rates and
CVVHDF ciprofloxacin clearance rates in the current
study, there is a suggested trend (r
2 = 0.94) of increasing
ciprofloxacin clearance with higher effluent fluid flow
rates, which is illustrated in Figure 2.
Pharmacokinetic - Pharmacodynamic parameters
The PK-PD parameters, Cpmax/MIC ratios and the ratio
of AUC0-24 /MIC, achieved with a ciprofloxacin dosing
regimen of 400 mg ciprofloxacin every 12 hours are
summarised in Table 4.
The median AUC0-24/MIC ratio for patients adminis-
tered Ciprofloxacin 400 mg twice daily was 161. An
AUC0-24/MIC~ > 100 has been propounded as an indi-
cator of adequate ciprofloxacin dosing [12].
Discussion
The pharmacokinetic parameter estimates obtained, half
life [median 13.8 (range 5.15-39.4) hours], TBC [median
9.90 (range 3.10-13.2) L/hr] and median Vdss of 125
(range 79.5-555) L illustrate the high level of inter-
patient variability in ciprofloxacin disposition in criti-
cally ill patients during CVVHDF. The t1/2 of ciprofloxa-
cin, approximately 4 hours in patients with normal renal
function, doubles in patients with severe renal impair-
ment. In general, accumulation will not be observed
with 12 hour dosing as this interval is greater than the
half-life, in patients without liver dysfunction. As signifi-
cant accumulation was observed with an interval of
eight hours in previous studies [15,17,25] a longer
dosage interval of 12 hours for patients on CVVHDF
should therefore be considered. Patients 1,4,6 and 7 had
Table 3 Ciprofloxacin and Creatinine Clearance by continuous veno-venous haemodiafiltration.
Patient ClCVVHDF
(L/hr)
ClCREAT
(L/hr)
FCVVHDF Measured effluent
fluid rate
(L/hr)
Total Body
Clearance
(L/hr)
1 A 2.8 2.9 0.25 4.0 11.3
2 C 2.4 2.6 0.31 3.4 7.72
3 B 2.7 2.9 0.27 3.9 9.96
4 A 2.3 2.3 0.74 2.9 3.10
5 A 2.2 2.6 0.22 3.0 9.90
6 C 2.1 2.4 0.26 2.9 8.06
7 B 2.8 2.9 0.28 4.0 10.1
Mean +/- SD 2.47 +/- 0.29 2.66 +/- 0.25 0.26 ± 0.03* 3.35 +/- 0.50 8.60 ± 2.7
* Excluding value from patient 4A
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and 7) to greater than 25 hours (patients 1 and 4),
demonstrating the variability of pharmacokinetic profiles
in this patient group, and also likely reflecting decreased
hepatic clearance in these four patients.
Wallis et al [15] reported a similarly reduced cipro-
floxacin clearance in six patients with renal failure, trea-
ted with 200 mg ciprofloxacin three times daily during
CVVHDF therapy (0.06-0.25 L/hr/kg).
The median volume of distribution of 125 L (mean
185 +/- 155) is similar to values reported by Wallis et al
[15] (mean: 135+/- 27 L) estimated from six patients
treated with 200 mg every 8 hours and by Lipman et al
[18] (range: 0.77 - 2.52 L/kg) for critically ill patients.
The current patient sample showed greater variability:
Patient 1, in particular, had a very high Vdss of 539L.
The average Vdss for the other 6 patients was 126
+/-43L. These values compare well with those detailed
above from Wallis et al [15], and probably reflect more
typical Vdss values of ciprofloxacin in this patient popu-
lation. However, the high Vdss calculated from patient 1
serves as evidence of the unpredictable drug disposition
which can occur in critically ill patients, reflecting
greater degrees of capillary leak in keeping with the
severity of illness.
A practical and useful finding was that, within the
range studied, creatinine clearance may serve as a clin-
ical surrogate for ciprofloxacin clearance on CVVHDF.
This relationship is clinically important as ciprofloxa-
cin is not routinely assayed in most hospitals. The
relationship did not decline over the life of the filter.
This relationship may serve as a useful guide to dosing
ciprofloxacin within this range of creatinine clearance
values.
As effluent flow rates increased, there was a suggested
trend of increased ciprofloxacin clearance via CVVHDF.
However, there was no observed change in TBC with
increasing effluent flow rate. This illustrates the varying
role of compensatory and alternative elimination meth-
ods such as hepatic elimination. Further studies on this
association between effluent flow rate and ciprofloxacin
clearance via CVVHDF to investigate the presence of a
cause-effect relationship would be beneficial and may
helpfully influence dosing decisions. This is of impor-
tance in particular as increased effluent flow rates may
be used for purposes other than enhancing drug clear-
ance, and therefore TBC in such patients can be difficult
to estimate in the absence of plasma concentration data
and due to the varying influence of alternative elimina-
tion routes. Further insight into the effect of increasing
effluent flow rate on clearance via CVVHDF is therefore
desirable. Prospectively, such dosing considerations are
often hampered by the discrepancy between prescribed
and achieved flow rates.
CVVHDF was responsible for clearing approximately
one quarter of all ciprofloxacin eliminated. Its relative
contribution to ciprofloxacin TBC will be greatest in
patients with concurrent hepatic and renal dysfunction,
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Table 4 Cpmax/MIC ratios for representative MICs for
patients treated with 400 mg ciprofloxacin every 12
hours during critical illness and continuous veno-venous
haemodiafiltration therapy.
Patient
ID
Cpmax/MIC ratio
(MIC = O.5 mg/L)
AUC0-24/MIC ratio
(MIC = O.5 mg/L)
1 10.3 147
2 10.2 207
3 12.8 158
5 14.6 159
6 10.0 199
Spooner et al. BMC Clinical Pharmacology 2011, 11:11
http://www.biomedcentral.com/1472-6904/11/11
Page 6 of 9as in these patients, CVVHDF will become a proportio-
nately more significant route. Therefore care is required
in dosing patients with concurrent renal and hepatic
failure/impairment to avoid accumulation of ciprofloxa-
cin. Interestingly, clearance of ciprofloxacin via CVVH
of up to 25% has been reported [21], which is similar to
that observed in the current study using CVVHDF. This
implies that both dialysis parameters and patient specific
parameters have a role to play in the observed variability
in clearance via CRRT, in addition to the CRRT method
used.
There is now significant evidence that correct and
timely antibiotic choices will save more lives than vir-
tually all other ICU therapies [4,26]. A Cpmax/MIC ratio
of ~>10 has been suggested [9,11] as desirable and thus
a 400 mg twice daily regimen appears to achieve these
target concentrations during CVVHDF therapy (Table
4), 200 mg twice daily being inadequate. For ciprofloxa-
cin 400 mg twice daily, the median Cpmax achieved in
this study was 5.2 (range 5.0-7.3) mg/L (mean 5.8 ± 1.0
mg/L), which represented a median Cpmax/MIC ratio
(based on an MIC of 0.5 mg/L) of 10.3. The median
AUC0-24 was 80.4 (range 70.8-104) mg.hr/L (mean 83.0
± 11.1 mg.hr/L), which corresponds to a median AUC0-
24/MIC ratio of 161 (range 142-207). A suggested char-
acteristic of adequate dosing for ciprofloxacin is an
AUC0-24/MIC ratio > 100.
Wallis et al [15] reported lower Cpmax concentrations
and AUC0-24 values with a lower daily dose of 600 mg
ciprofloxacin, compared to the 800 mg daily dose used
in this study. The CVVHDF conditions in our study
were similar to those reported by Wallis et al [15].
Wallis et al [15] used a dosing schedule of 200 mg every
8 hours and the mean Cpmax concentration was 3.5 +/-
0.5 mg/L. This dosing schedule achieves on average a
Cpmax/ M I Cr a t i oo f7( b a s e do naM I Co f0 . 5m g / L ) .
The mean AUC0-24 achieved by the same dosing sche-
dule of 200 mg every 8 hours was 48.3 +/- 8.7 mg.h/L,
equivalent to a AUC0-24/ M I Cr a t i oo f9 6 . 6+ / -1 7 . 4 ,o n
t h eb a s i so faM I Cv a l u eo f0 . 5m g / L .M a l o n ee ta l[ 2 7 ]
reported a mean Cpmax of 3.9 mg/L (Cpmax /MIC ratio;
7.8) for three patients treated with 400 mg ciprofloxacin
every 24 hours during CVVHDF therapy. The mean
AUC0-24 with this dosing schedule was 56.8 mg.h/L,
which represents an AUC0-24/MIC ratio of 114 (assum-
ing an MIC of 0.5 mg/L). The CVVHDF conditions
employed by Malone et al [27] were different from
those used in the current work.
On the basis of these pharmacodynamic considera-
tions, the dosing schedule utilised in this study gives
better cover than previously studied dosage strategies
and should serve as a pharmacokinetically and pharma-
codynamically valid dose guide in the appropriate clini-
cal circumstances.
One limitation of this work is common to all carried
out in this field, that patient numbers are small, and as
such the conclusions that can be drawn are limited to a
very narrow patient cohort. A consideration for future
research might be that a randomised crossover design
could be employed to add further clarity to dosing
recommendations. As both antimicrobial doses, and dia-
lysis parameters such as flow rate, are frequently
adjusted on the basis of changing clinical need in the
intensive care setting, there are ethical difficulties sur-
rounding the set up and design of such trials.
Another limitation was that liver dysfunction or
impairment was not characterised in a standardised
manner. However this is difficult in these patients due
to blood product and vitamin K administration, particu-
larly in septic and coagulopathic patients and also
because of concurrent hepatotoxic drug administration.
Similarly, the varying nature from day to day of hepatic/
renal function in many critically ill patients suggest that
calculations based on steady state be interpreted with
caution, as clearance is likely to be variable. Further-
more, it is extremely difficult to quantify any residual
renal function, and thereby contribution to the clear-
ance, that these patients made have had.
Conclusion
Our results suggest that a dose rate of 400 mg every 12
hours, will achieve the recommended PK-PD goals in
most patients on CVVHDF. Twice daily dosing of cipro-
floxacin maximised peak concentrations, while minimiz-
ing accumulation. Concomitant hepatic and renal
dysfunction results in a prolonged elimination half-life.
Creatinine clearance by the filter may be used to esti-
mate ciprofloxacin clearance by CVVHDF (within the
range studied). Thus in the absence of ciprofloxacin
plasma levels, creatinine clearance by the filter could be
considered as a surrogate marker for ciprofloxacin clear-
ance in patients, this may be particularly useful when
other routes of elimination are impaired.
The data suggest that drug clearance increases with
increasing effluent flow rate, which in turn may require
even higher ciprofloxacin dosing. This association
between effluent flow rate and drug clearance requires
further elucidation to determine the nature of any
cause-effect relationship.
While a 400 mg dose administered at 12 hourly inter-
vals achieved adequate Cpmax concentrations and lower
doses may result in target serum concentrations in some
patients with hepatic dysfunction, given the general
emergence of ciprofloxacin resistance and the wide ther-
apeutic index of ciprofloxacin, it may be advisable to
maintain the higher ciprofloxacin dose as the mainstay
of therapy. The possibility of accumulation in patients
where more than one elimination route is impaired
Spooner et al. BMC Clinical Pharmacology 2011, 11:11
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Page 7 of 9should be considered and this can be addressed by
extension of the dosage interval.
Key Messages
￿ Ciprofloxacin 400 mg twice daily IV will achieve
the recommended PK-PD goal (AUC0-24/MIC ratio
>125) in most patients on CVVHDF.
￿ Concomitant hepatic and renal impairment results
in a prolonged ciprofloxacin elimination half life,
therefore dosage interval extension may be required.
￿ Creatinine clearance by the filter correlates well
with ciprofloxacin clearance by the filter, therefore
creatinine clearance by the filter (in the range stu-
died) may be used as a surrogate for ciprofloxacin
clearance.
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